🏛️ Verified NIH Record • Updated 2026-08-13
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis (NCT07290569)
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Oruka Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Who can join: Review the eligibility criteria below.
Location: Oruka Therapeutics Investigative Site — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- Oruka Therapeutics Investigative Site — Phoenix, Arizona
- Oruka Therapeutics Investigative Site — North Little Rock, Arkansas
- Oruka Therapeutics Investigative Site — Los Angeles, California
- Oruka Therapeutics Investigative Site — Los Angeles, California
- Oruka Therapeutics Investigative Site — San Diego, California
- Oruka Therapeutics Investigative Site — Miami, Florida
- Oruka Therapeutics Investigative Site — Rolling Meadows, Illinois
- Oruka Therapeutics Investigative Site — Plainfield, Indiana
- Oruka Therapeutics Investigative Site — Rockville, Maryland
- Oruka Therapeutics Investigative Site — Kew Gardens, New York
- Oruka Therapeutics Investigative Site — Chapel Hill, North Carolina
- Oruka Therapeutics Investigative Site — Cleveland, Ohio
- Oruka Therapeutics Investigative Site — Mason, Ohio
- Oruka Therapeutics Investigative Site — Portland, Oregon
- Oruka Therapeutics Investigative Site — Portland, Oregon
- Oruka Therapeutics Investigative Site — Philadelphia, Pennsylvania
- Oruka Therapeutics Investigative Site — Frisco, Texas
- Oruka Therapeutics Investigative Site — Houston, Texas
- Oruka Therapeutics Investigative Site — Webster, Texas
- Oruka Therapeutics Investigative Site — Norfolk, Virginia
- Oruka Therapeutics Investigative Site — Surrey, British Columbia
- Oruka Therapeutics Investigative Site — Surrey, British Columbia
- Oruka Therapeutics Investigative Site — Fredericton, New Brunswick
- Oruka Therapeutics Investigative Site — Ajax, Ontario
- Oruka Therapeutics Investigative Site — Markham, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.